BNP Paribas Asset Management
CAPR icon

BNP Paribas Asset Management’s Capricor Therapeutics CAPR Stock Holding History

BNP Paribas Asset Management’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.3K Sell
717
-121
-14% -$3.67K ﹤0.01% 2088
2026
Q1 		$25.5K Buy
+838
New +$22.3K ﹤0.01% 1952
2025
Q3 		– Sell
-448
Closed -$4K – 1897
2025
Q2 		$4K Buy
+448
New +$4.73K ﹤0.01% 2070

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BNP Paribas Asset Management's CAPR Position: Q2 2026 in Review

BNP Paribas Asset Management reduced its Capricor Therapeutics (CAPR) stake by 14% in Q2 2026, selling an estimated $3.67K and leaving 717 shares worth $17.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2088.

BNP Paribas Asset Management first reported a position in CAPR in Q2 2025 and has held it in 3 quarters since. The position peaked at $25.5K in Q1 2026. 169 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • BNP Paribas Asset Management held 717 shares of Capricor Therapeutics worth $17.3K as of Q2 2026.
  • BNP Paribas Asset Management sold 121 Capricor Therapeutics shares in Q2 2026, an estimated $3.67K.
  • Capricor Therapeutics made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q2 2026, its #2088 holding.
  • BNP Paribas Asset Management first reported a position in Capricor Therapeutics in Q2 2025 and has held it in 3 quarters since.
  • BNP Paribas Asset Management's Capricor Therapeutics position peaked at $25.5K in Q1 2026.
  • 169 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.